Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
P/B ratio for Day One Biopharmaceuticals, Inc. (DAWN)
P/B ratio as of 2023: 3.36
According to Day One Biopharmaceuticals, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 3.36. At the end of 2022 the company had a P/B ratio of -5.22.
P/B ratio history for Day One Biopharmaceuticals, Inc. from 2019 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 3.36 |
| 2022 | -5.22 |
| 2021 | -8.19 |
| 2020 | -26.85 |
| 2019 | -136.36 |